- Conditions
- Small Intestinal Bacterial Overgrowth, Irritable Bowel Syndrome, Functional Dyspepsia, Functional Abdominal Pain
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 6,354
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn Disease
- Interventions
- Tulisokibart, Companion Diagnostic (CDx)
- Biological · Diagnostic Test
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Liberty, Kansas • Chesterfield, Michigan + 11 more
- Conditions
- Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid, Pelvic Venous Disorders, Peripheral Aneurysms, Portal Vein Embolization, Type II Endoleak, Varicocele, Hemorrhage
- Interventions
- Concerto Versa™ Detachable Coils
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Piscataway, New Jersey • New York, New York • El Paso, Texas
- Conditions
- Obesity, Childhood
- Interventions
- Not listed
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 6 Weeks to 3 Months
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
- Biological · Drug · Procedure
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- TRYP-0082, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- TRYP Therapeutics
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PB1046 Subcutaneous Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
- Interventions
- Placebo, Rifaximin
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 35 Years to 72 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
- Interventions
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Interventions
- Hormone biomarker analysis, QoL Questionnaires
- Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Device · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Brain Injury, Chronic, Brain Injuries, Traumatic
- Interventions
- Inulin fructooligosaccharide
- Dietary Supplement
- Lead sponsor
- Centre for Neuro Skills
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bakersfield, California
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, irinotecan hydrochloride, oglufanide disodium
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
- Conditions
- Cancer, Bowel Dysfunction
- Interventions
- alvimopan, placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 14
- States / cities
- Duarte, California • Fountain Valley, California • La Verne, California + 11 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Third Eye Panoramic device
- Device
- Lead sponsor
- Avantis Medical Systems
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Flushing, New York
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
- Drug · Combination Product · Other
- Lead sponsor
- Epkin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Santa Monica, California • Houston, Texas
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
- Radiation · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fecal Incontinence
- Interventions
- Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
- Other · Dietary Supplement · Drug + 1 more
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Short Bowel Syndrome
- Interventions
- NM-002
- Drug
- Lead sponsor
- 9 Meters Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
- Interventions
- ABBV-253
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
- Conditions
- Colon Cancer, Rectum Cancer
- Interventions
- Cetuximab, Irinotecan
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Virtual reality-directed BGBT
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Anal Cancer
- Interventions
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 169
- States / cities
- Tucson, Arizona • Auburn, California • Burbank, California + 128 more